Agata Grochowska: Thromboprophylaxis and Coagulation Challenges in Pancreatic Cancer
Agata Grochowska, Ambassador and Teaching Assistant at Meta-Analysis Academy, shared on LinkedIn about a recent article she and her colleagues co-authored, adding:
”New Publication Alert | Thromboprophylaxis and Coagulation Challenges in Pancreatic Cancer
Published in Journal of Thrombosis and Thrombolysis (IF 2.2)
February 20, 2026
I’m pleased to share our latest review: ‘Coagulation disorders and thromboprophylaxis in pancreatic cancer: a review of current evidence and clinical challenges.’
Pancreatic cancer is still one of the most thrombogenic malignancies.
Venous thromboembolism (VTE) is more than just a clinical problem, playing a crucial role in survival, postoperative recovery, and the ability to deliver systemic therapy.
Highlights from our review:
- Thrombosis associated with pancreatic cancer is among the highest-risk cancers.
- Standard prophylactic dosing is widely recommended, yet largely extrapolated from non-pancreatic cancer data.
- Increased low-molecular-weight heparin (LMWH) treatment plans are effective in reducing VTE in advanced disease, but with no evidence of a survival benefit.
- Direct oral anticoagulants (DOACs) offer convenience but raise concerns regarding gastrointestinal bleeding.
- Post-pancreatectomy VTE occurs in 20-25% of patients within 90 days, with many events occurring after hospital discharge.
- Post-pancreatectomy hemorrhage (PPH) poses a fundamental therapeutic issue: when and how to safely resume anticoagulation remains insufficiently defined.
The central challenge: balancing thrombosis prevention with bleeding risk in one of the most complex oncologic surgical populations.
Our review highlights the urgent need for pancreatic cancer-specific randomized trials and clearer perioperative anticoagulation strategies.
Pancreatic cancer care is not only about resection margins and chemotherapy protocols; it is also about understanding and managing the profound hemostatic imbalance that defines this disease.
A huge thank you to the co-authors: Dr. Julia Kaczorowska, Dr. Maciej Świerczyna, Dr. Wojciech Ciesielski, Prof. Adam Durczyński, Prof. Janusz Strzelczyk, and Prof. Piotr Hogendorf from the Department of General and Transplant Surgery, Medical University of Lodz.”
Title: Coagulation disorders and thromboprophylaxis in pancreatic cancer: a review of current evidence and clinical challenges
Authors: Agata Grochowska, Julia Kaczorowska, Maciej Świerczyna, Wojciech Ciesielski, Adam Durczyński, Janusz Strzelczyk, Piotr Hogendorf
Read the Full Article on Journal of Thrombosis and Thrombolysis
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 12, 2026, 17:04Marc Carrier: EPCAT III Trial at ISTH 2026 Supports Aspirin Alone for VTE Prevention After Arthroplasty
-
Jul 12, 2026, 16:15Louise St. Germain Bannon: Global Collaboration Is Key to Turning Scientific Innovation Into Better Care
-
Jul 12, 2026, 16:10Marc Carrier: Major Scientific Highlight Confirms the Safety of the YEARS Algorithm at ISTH 2026
-
Jul 12, 2026, 16:01Joseph R. Shaw: Sharing New Insights into Antithrombotic Therapy and Thrombin Generation at ISTH 2026
-
Jul 12, 2026, 15:45Nathan Connell: Key Clinical Advances in Heavy Menstrual Bleeding and Postpartum Hemorrhage from ISTH 2026
-
Jul 12, 2026, 15:40Anne-Claire Duchez: Join Us at ISTH 2026 to Discover Our Latest Research and Meet the Team
-
Jul 12, 2026, 12:30Reduced-Dose DOACs in GI Malignancies: Toward Personalized Anticoagulation
-
Jul 12, 2026, 08:50Where the Hemophilia Community Comes Together at ISTH 2026 – EAHAD
-
Jul 12, 2026, 08:2210 Posts Not To Miss from ISTH 2026, Part 1